Abstract:Proc Amer Assoc Cancer Res, Volume 47, 2006 3972 Prostate cancer (CaP) commonly metastasizes to bone resulting in high mortality. Strategies to inhibit prostate cancer metastasis include targeting both tumor-induced osteoblastic lesions and underlined, possibly prerequisite, osteoclastic activities at the bone metastatic sites. We have previously demonstrated that blocking receptor activator of NFκB ligand (RANKL) partially prevent the establishment of CaP in bone and diminishes the progression of CaP growth in the skeleton in murine models. However, RANKL in the serum from CaP patients or from the bone marrow of tumor sites in animal models or in the cell lines used in those studies was at very low level. These findings strongly suggest that soluble factors other than RANKL may mediate the tumor-induced osteclast activity. To identify these factors we first used a human cytokine antibody array (174 cytokines) to measure cytokine protein expression in conditioned medium (CM) collected from CaP cells LNCaP and C4-2B (the derivative from LNCaP but with bone metastastatic characteristics). We found that both cells produced significantly high amount of several cytokines such as IL-8 and MCP-1, but not IL-6, IL-11, TNFα, MIP-1α, and RANTES. Furthermore, IGFBP-2 and MMP-9 were found significantly higher in C4-2B CM than LNCaP CM. (4.4-fold for IGFBP-2 and 3.1-fold for MMP-9). These results were confirmed by using ELISA. Finally, murine osteoclast precursor RAW264.7, cells or human bone marrow-derived monocytes were cultured with LNCaP CM (10%). Within 24 hours, LNCaP-CM induced multinucleated TRAP positive osteoclast formation from RAW264.7 cells while the soluble RANKL (50ng/ml) required 96 hours to form mature osteoclasts. Recombinant human IL-8 (10ng/ml), but not MCP-1 (10ng/ml), directly stimulated Raw 264.7 differentiation into mature osteoclast and bone resorption on dentin slices within 6 days of culture in the absence of RANKL. LNCaP-CM-induced osteoclast formation and bone resorption from RAW264.7 cells and human bone marrow-derived monocytes (HBMC) were dose-dependently inhibited by adding anti-IL-8 neutralizing antibody and further synergistically inhibited with addition of MCP-1 antibody in HBMC. In summary, we have identified IL-8 and MCP-1 that produced by CaP cells directly induce osteoclastogenesis and bone resorption in vitro. Together with recent report that serum IL-8 level is elevated in men with CaP and bone metastases and MCP-1 as a key mediator involved in the recruitment of monocytes/macrophages in inflamed bone, this study may provide a targeting strategy for the treatment of CaP skeletal metastasis.

Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) Drives Activation of Bone Remodelling and Skeletal Metastasis

CCL2/Monocyte Chemoattractant Protein 1 and Parathyroid Hormone Action on Bone

Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone

Monocyte Chemotactic Protein-1 Mediates Prostate Cancer-Induced Bone Resorption

Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo

Monocyte Chemotactic Protein-1 Promotes the Proliferation and Invasion of Osteosarcoma Cells and Upregulates the Expression of Akt

PTHrP‐induced MCP‐1 Production by Human Bone Marrow Endothelial Cells and Osteoblasts Promotes Osteoclast Differentiation and Prostate Cancer Cell Proliferation and Invasion in Vitro

The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasis

Prostate Cancer Cells Induce Osteoclastogenesis And Bone Resorption Through Rankl-Independent Interleukin-8 (Il-8) And Monocyte Chemoattractant Protein-1 (Mcp-1) Production

A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone

The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?

The molecular structure and role of CCL2 (MCP‐1) and C‐C chemokine receptor CCR2 in skeletal biology and diseases

Monocyte Chemoattractant Protein-1/CCL2 Produced by Stromal Cells Promotes Lung Metastasis of 4T1 Murine Breast Cancer Cells

Monocyte Chemotactic Protein-1 (MCP-1) Acts As a Paracrine and Autocrine Factor for Prostate Cancer Growth and Invasion

Role of Tumor-Derived Chemokines in Osteolytic Bone Metastasis

The Role of the Calcitonin Peptide Family in Prostate Cancer and Bone Metastasis

Monocyte Chemoattractant Protein-1 promotes cancer cell migration via c-Raf/MAPK/AP-1 pathway and MMP-9 production in osteosarcoma

The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments

MCP-1: Function, regulation, and involvement in disease

The MCP-3/Ccr3 axis contributes to increased bone mass by affecting osteoblast and osteoclast differentiation

Monocyte-derived Macrophages Promote Breast Cancer Bone Metastasis Outgrowth.